From eResearchTechnology to ERT
News Feb 25, 2009
ERT has announced that, following extensive external and internal assessment, it is launching its new branding. Formerly eResearchTechnology, Inc., the company has adopted an entirely new image and character for the company following staff feedback and customer affirmation of its core values.
According to ERT, the business found that both customers and employees expect and receive a commitment from ERT that it will get the job done, and right. ERT is a dynamic and proactive organization that is committed to redefining and setting new standards of how clinical trials are successfully conducted.
This new brand strategy brings an enhanced visual identity to market as well as sharpened product positioning, a new web site, messaging and corporate collateral.
As part of its new branding commitment ERT has introduced a new platform of products and services in the clinical trials arena to its customers worldwide. This consists of four sub-brands for ERT’s products and services: Cardiac Safety Solutions; EDC Solutions; ePRO Solutions and ERT Clinical Research Consulting Group. Cardiac Safety, EDC and ePRO Solutions are founded upon the company’s innovative technology platform – EXPERT™.
EXPERT™ is a robust, secure and validated clinical-research workflow-processing system that powers centralized electronic data collection, data management and information exchange. All of ERT’s solutions are supported by cross-functional teams operating within its SOP-driven, Project Assurance methodology that delivers exceptional performance metrics and customer satisfaction.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.